Omalizumab (Xolair)

What is omalizumab?

Omalizumab (Xolair) is a biologic medication specifically designed to target and inhibit immunoglobulin E (IgE), a protein in the immune system that plays a significant role in chronic urticaria (hives). It is often employed as a second-line treatment for individuals whose symptoms persist despite antihistamine therapy. The majority of patients who utilize omalizumab for chronic urticaria find substantial relief and can maintain a symptom-free state.

What are possible side effects of omalizumab?

The most severe, although rare, side effect of omalizumab is anaphylaxis, a life-threatening allergic reaction. As a precautionary measure, patients are prescribed an EpiPen and monitored in a clinical setting for the initial doses to ensure that no adverse reactions occur.

How is omalizumab used?

Omalizumab is administered as a subcutaneous (under the skin) injection on a monthly basis. After the initial few doses, which are closely monitored in a clinical setting, patients often have the option to self-administer the injections at home, provided they feel comfortable doing so. Alternatively, monthly clinic visits can continue for those who prefer professional administration.